A molecule that targets a cell’s mechanism for breaking down unneeded proteins can kill multiple myeloma cancer cells that have become resistant to bortezomib and other myeloma drugs, researchers at Dana-Farber Cancer Institute have found.
Lead investigator Dharminder Chauhan, PhD, described the research in an interview with Value-Based Care in Myeloma. The results of the study were recently published (Chauhan D, et al. Cancer Cell. 2012;22:345-358).
The increased risk of reactivation of the varicella zoster virus (VZV) infection (a type of herpes zoster) observed in previous studies of bortezomib-based therapy was completely abrogated in patients with multiple myeloma who received prophylaxis with acyclovir, in a series of patients treated at Roswell Park Cancer Institute, Buffalo, NY.
Results 1 - 6 of 6